This proposal is an important patient safety action. FDA-approved GLP-1 medications are reviewed for safety, effectiveness, quality, consistency, and labeling. Patients deserve to know what is in their medication, how it was manufactured, and whether it meets FDA quality standards.

For communities that have historically faced healthcare disparities, access to safe, regulated, and transparent medications is essential. Patients should not be exposed to unnecessary risks from compounded products when FDA-approved therapies are available and appropriate.

The National Minority Quality Forum believes patient safety, transparency, and accountability must remain at the center of decisions affecting public health.

Tell FDA to finalize its proposal and continue protecting patients through strong GLP-1 safety standards.

The public comment period closes June 30, 2026. Take action today and make your voice heard.